Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence;Transarterielle chemoperfusion des inoperablen pankreaskarzinoms und lokalrezidivs

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 175, Issue 5, 2003, Pages 695-704

  Vogl, Thomas J ^a   Heller, M ^a   Zangos, S ^a   Schwarz, W ^a   Eichler, K ^a   Mack, M G ^a   Berger, D ^b   Balzer, J O ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Stadtklinik Baden   (Germany)

Author keywords

Gemcitabine; Mitomycin C; Pancreatic carcinoma; Transarterial locoregional chemoperfusion

Indexed keywords

CISPLATIN; CONTRAST MEDIUM; DOCETAXEL; EPIRUBICIN; GADOLINIUM PENTETATE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITO MEDAC; MITOMYCIN C;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CATHETER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; INOPERABLE CANCER; MALE; METASTASIS; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; PANCREAS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REGIONAL PERFUSION; SIDE EFFECT; THROMBOCYTOPENIA; TRANSARTERIAL CHEMOPERFUSION; TUMOR VOLUME; VOMITING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037864105     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39212     Document Type: Article

References (25)

1. Warshaw AL, Castillo CF. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465
2. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6 (1): 19-28
3. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26 (6): 589-605
4. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as a first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (6): 2403-2413
5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12 (1): 29-34
6. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris 3rd HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7 (4): 347-353
7. Bengmark S, Andren-Sandberg A. Infusion chemotherapy in inoperable pancreatic carcinoma. Recent Results Cancer Res 1983; 86: 13-14
8. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9 (12): 2128-2133
9. Wadler S, Damle S, Haynes H, Kaleya R, Schechner R, Berkenblit R, Ladner RD, Murgo A. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. J Clin Oncol 1999; 17 (6): 1771-1778
10. Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15 (6): 2414-2419
11. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33 (Suppl 1): S18-22
12. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anticancer Drugs 1998; 9 (3): 191-201
13. Stehlin JS, Giovanella BC, Natelson EA, De Ipolyi PD, Coil D, Davis B, Wolk D, Wallace P, Trojacek A. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14 (5): 821-831
14. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 18; 81 (2): 116-124
15. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142 (5): 1534-1543
16. Kurtz JE, Trillet-Lenoir V, Bugat R, Negrier S, Adenis A, Kayitalire L, Ripoche V, Dufour P. Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study. Bull Cancer 1999; 86 (2): 202-206
17. Moore MJ, Hamm J, Eisenberg P, Degenais M, Hagan K, Fiels A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY. 12-9566 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 930
18. Meyer F, Hirbaschek A, Kuhn R, Eichelmann K, Luck A, Lipper H, Ridlewski K. Antineoplastic effect and quality of life in patients with pancreatic carcinoma who received gemcitabine monotherapy. Visceralchirurgie 2000; 36: 85-90
19. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001; 31 (1): 7-12
20. Scheithauer W, Kornek GV, Raderer M, Hejna M, Valencak J, Miholic J, Kovats E, Lang F, Funovics J, Bareck E, Depisch D. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 1999; 80 (11): 1797-1802
21. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94 (1): 97-103
22. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 15: 94 (4): 902-910
23. Spagnuolo P, Roversi R, Rossi G, Ricci S, Calandri C, Cavallo G, Marrocolo F, Crino L. Phase II study of gemcitabine as locoregional treatment of advanced pancreatic cancer. Proc Am Soc Clin Oncol 1999; 18: 1153
24. Weissmann A, Ludwig H. Intraarterial gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma. Proc Am Soc Clin Oncol 1999; 18: 1170
25. Klapdor R, Seutter E, Lang-Polckow EM, Reichle H, Hinrichs A. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 1999; 19 (4A): 2459-2469